FNDC5 and sarcopenia: Additionally, in the longitudinal analysis, participants with the greatest 3‐year increases in irisin had higher odds of obesity, abdominal obesity, sarcopenia, low ALST and sarcopenic obesity at follow‐up compared to those with the least increase or with decreased irisin.